Merck to buy Prometheus Biosciences for about $11 billion
Economy And Jobs,Pharmaceuticals,Big Pharma,Banking And Finance,Acquisitions
From the Center
AllSides Media Bias Rating: Center
Merck & Co (MRK.N) has agreed to acquire Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
The joint statement said that Merck, through one of its subsidiaries, will pay $200 per share for the biotechnology company that specializes in products for treatment of immunological diseases. That represents a 75% premium to the $114.01 closing price for Prometheus shares on Friday.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
AllSides Picks
Headline Roundup
Trump's Plan to Import Beef Sparks Republican Pushback, Conspiracy Theories
August 25th, 2026
Headline Roundup
US National Debt Surpasses $40 Trillion, Renewing Debate Over Fiscal Outlook
August 20th, 2026
News
Tracking Trump’s Campaign Promises
AllSides Staff
August 13th, 2026
Story of the Week
Affordability in America
AllSides Staff
August 13th, 2026
More News about Economy and Jobs
News from the Left
News from the Center
News from the Right
Trump fires back at Canada after Carney suspends trade talks, accuses US of last-minute 'power play'
Fox Business
